WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Subject: search.filters.subject.chemoradiotherapy

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Evaluation of the relationship between serum ghrelin levels and cancer cachexia in patients with locally advanced nonsmall-cell lung cancer treated with chemoradiotherapy
    (WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020-01-01) Uysal, Pelin; Afsar, Cigdem Usul; Sozer, Volkan; Inanc, Berrin; Agaoglu, Fulya; Gural, Zeynep; Fazlioglu, Nevin Gural; Cuhadaroglu, Caglar; Uzun, Hafize
    Background: Ghrelin plays a role in mechanisms related to cancer progression - including cell proliferation, invasion and migration, and resistance to apoptosis in the cell lines from several cancers. We investigated the role of ghrelin levels in cancer cachexia-anorexia in patients with locally advanced nonsmall-cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT). Materials and Methods: This study involved 84 NSCLC patients who had received concomitant CRT. Blood ghrelin levels were compared before and 3 months after CRT. Meanwhile, changes in body weight of the patients were also investigated with changes in ghrelin levels before and after CRT. Results: Ghrelin levels were significantly decreased in line with changes in patients' weights in patients receiving CRT (P < 0.001). Serum albumin levels and inflammatory-nutritional index were significantly decreased after radiotherapy (RT) (3.01 0.40 g/dL, 0.38 +/- 0.20) when compared with its baseline levels (3.40 +/- 0.55 g/dL,P < 0.001
  • Thumbnail Image
    Item
    Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy
    (WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2021-01-01) Yucel, Serap; Kadioglu, Huseyin; Gural, Zeynep; Akgun, Zuleyha; Saglam, Esra Kaytan
    Aims: To evaluate the results of chemoradiation with intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) for the treatment of anal canal cancer patients at three institutions that had advanced devices. Materials and Methods: A retrospective analysis was performed for patients treated with 5-fluorouracil and mitomycin-based chemotherapy and IMRT or VMAT for anal cancer from 2011 to 2013. Complete response (CR) rates, colostomy-free survival (CFS), disease-free survival (DFS), overall survival (OS), and toxicities were investigated. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events, Version 3.0. Results: Fifteen patients were included in the analysis. The majority of patients had T2 (53.3\%) and N0 (40\%) disease according to the staging system that was developed by the American Joint Committee on Cancer. CR was observed in 14 patients (93\%), and the median follow-up was 26 months (13-42 months). The 3-year CFS, DFS, and OS were 86\%, 86\%, and 88\%, respectively. Acute Grade 3 toxicities were observed as 6\% of hematological, 26\% of gastrointestinal, and 26\% of dermatological. Conclusion: Early results confirm that IMRT or VMAT for anal cancer treatment reduces acute toxicities while maintaining high control rates.
  • Thumbnail Image
    Item
    Concurrent chemoradiotherapy with weekly carboplatin and paclitaxel may be a feasible option in inoperable stage III non-small cell lung cancer: a single center experience
    (CUKUROVA UNIV, FAC MEDICINE, 2019-01-01) Calikusu, Zuleyha; Sedef, Ali Murat; Saltaoglu, Pinar
    Purpose: Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). An optimal chemotherapy regimen with concurrent thoracic radiotherapy is not known. In this study, we investigated the efficacy and toxicity of CCRT with carboplatin {[}area under curve (AUC) 2] and paclitaxel (80 mg/m(2)) during CCRT. Materials and Methods: We performed a retrospective survival analysis using medical records of 40 patients with inoperable stage III NSCLC that were treated with concurrent chemoradiotherapy with carboplatin-paclitaxel (AUC 2, 60 mg/m2). Results: The most common histopathology was adenocarcinoma, which was diagnosed in 18 patients (45\%). There were 12 stage IIIA patients (30\%) and 28 stage IIIB patients (70\%). The median follow-up time was 22.5 months {[}95\% confidence interval (CI), 2.9-72.2]. Median disease-free survival (DFS) and overall survival (OS) were 22.5 months (95\% CI, 18.1-27.0) and 53.5 months (95\% CI, 23.5-82.8). Grade 3-4 hematological and non-hematological toxicities were seen in 8 (20\%) and 5 (12.5\%) patients, respectively. Conclusion: This study showed that CCRT with weekly carboplatin-paclitaxel provides similar outcomes to cases in the literature and the regimen seems to be feasible with a low rate of grade 3-4 toxicity during CCRT of non operable stage III NSCLC. Keywords: Carboplatin, non-small cell lung cancer, chemoradiotherapy, paclitaxel